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Abstract
Background: High purity of tumour samples is a necessity for accurate genetic and expression
analysis and is usually achieved by positive selection in chronic lymphocytic leukaemia (CLL).
Results: We adapted a bifunctional rosette-based antibody cocktail for negative selection of B-
cells for isolating CLL cells from peripheral blood (PB). PB samples from CLL patients were split
into aliquots. One aliquot of each sample was enriched by density gradient centrifugation (DGC),
while the other aliquot of each sample was incubated with an antibody cocktail for B-cell
enrichment prior to DGC (RS+DGC). The purity of CLL cells after DGC averaged 74.1% (range:
15.9 – 97.4%). Using RS+DGC, the purity averaged 93.8% (range: 80.4 – 99.4%) with 23 of 29 (79%)
samples showing CLL purities above 90%. RNA extracted from enriched CLL cells was of
appropriately high quality for microarray analysis.
Conclusion: This study confirms the use of a bifunctional rosette-based antibody cocktail as an
effective method for the purification of CLL cells from peripheral blood.
Background
Enrichment of tumour cells to a purity of more than 90%
is highly desirable for accurate results in many applica-
tions, especially for RT-PCR and microarray based expres-
sion analysis [1,2]. In B-cell chronic lymphocytic
leukaemia (CLL), such purities have usually been
achieved by density gradient centrifugation (DGC) and
subsequent fluorescent-activated cell sorting (FACS) or by
magnetic cell sorting (MCS) for CD19 positive cells [1].
Studies focusing on expression analysis in CLL utilising
microarrays report median purities of 88 and 90% of
CD19 positive cells using DGC [3,4] though it is likely
that selection occurred for samples with high purity. One
study applying DGC and FACS of mononuclear cells
reported purities of between 90 and 95% of CD5–CD19
co-expressing cells [5]. Three studies [6-8] reported puri-
ties higher than 97% of CD19 positive cells after DGC and
MCS. Although high purity is achieved with FACS and
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MCS, both are time and cost intensive procedures which
often are limited in terms of tumour cell yields and appli-
cability, since they require expensive equipment and the
processing time depends on the sample volume. Another
potential disadvantage is that they are positive selection
approaches which might alter gene expression through
the activation of cell surface receptors [1].
Our study focused on adapting a negative selection
method that could offer the required purity after the DGC
step thereby markedly cutting down the time and cost of
sample processing and reducing the risk of altering the
gene expression pattern.
We used a bifunctional antibody cocktail for B-cell enrich-
ment (RosetteSep™ (RS)) that binds erythrocytes (via glyc-
ophorin) on one side and white cell populations other
than B-cells (via the CD2, CD3, CD16, CD36, CD56 and/
or CD66b antigens) on the other side thus forming dense
rosettes of erythrocytes surrounding the unwanted white
blood cells when added to whole blood. The increased
density of the rosetted cells results in their pelleting by
subsequent DGC. This combination of RS incubation and
subsequent density gradient centrifugation (RS+DGC)
thus results in the depletion of undesired cells and leaves
purified B-cells behind that can be harvested from the
interface [9]. Here, we investigate whether RS+DGC can
also effectively isolate CLL cells at high purity from
peripheral blood (PB).
Results and Discussion
A preliminary experiment was used to assess the optimal
RS concentration that resulted in the best purity. Aliquots
of three CLL samples were treated with 50, 60, 70 and 80
μl RS/ml PB to monitor the effect on the resulting purity.
The experiments indicated that a concentration of 70 μl
RS/ml PB resulted in the best purity (see Additional File
1). This was the concentration used to subsequently
enrich all CLL samples.
Enrichment with RS+DGC was performed in less than 90
minutes and showed higher purities of CD5/CD19 co-
expressing cells for every sample compared to the enrich-
ment with DGC alone. The analysed PB samples of CLL
patients showed an average CLL cell purity of 74.1%
(ranging from 15.9 to 97.4%) after DGC (see Figure 1A
and Additional Files 2 and 3). After RS+DGC enrichment,
the same samples exhibited an average CLL cell purity of
93.8% (ranging from 80.4 to 99.4%). The average purity
of CD5/CD19 co-expressing cells was raised from 74.1%
after DGC to 93.8% after RS+DGC. The average percent-
age of CD5- CD19+ (normal B-cells), CD5- CD19- (natural
killer cells and monocytes) and CD5+ CD19- cells (T-cells)
was reduced from 1.4, 10.1 and 14.4 to 1.0, 3.5 and 1.6%
respectively after RS+DGC (see Additional File 3).
The purity of the enriched CLL cells (based on CD5/CD19
co-expression) increased with the WBC count of the sam-
ples (see Figure 1A). RS+DGC enrichment resulted in a
CLL purity of greater than 90% for all 23 of the 29 samples
that showed a WBC count higher than 20 × 106cells/ml
PB, while the 6 samples with a WBC count between 7 and
20 × 106cells/ml PB showed CLL purity between 80 and
90% after RS+DGC enrichment. The consistently higher
purities achieved with RS+DGC in all 29 samples com-
pared to DGC alone show the efficacy of the rosette based
enrichment method, and is comparable with purities
achieved by MCS and FACS and superior in terms of time
and cost (see Table 1).
Not surprisingly, the cell yield also depended on the WBC
count (see Figure 1B and Additional File 4). The number
of cells harvested can be regulated by increasing (or
decreasing) the volume of blood to be processed and by
adjusting the volume of added RS antibody cocktail
accordingly without any effect on the processing time of
90 minutes. This is another potential advantage over
FACS and MCS where increased cell numbers require
increased processing time.
purity of CD5+ CD19+ cells in the same sample after DGC  or RS+DGC enrichment (A) and absolute yield of WBCs  after RS+DGC enrichment (B) plotted against the respective  white blood cell count Figure 1
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The RNA extracted from enriched cells using RS+DGC dis-
played an average RIN of 8.9 (ranging from 7.7 to 9.5),
indicating high-quality RNA (see Additional File 3) that
subsequently gave excellent results on microarray analysis
(data not shown).
Conclusion
This study shows that negative selection using a bifunc-
tional rosette-based antibody cocktail is an effective
method to isolate CLL cells of high purity, especially in
samples with a WBC count above 20 × 106 cells/ml. The
short purification time, the independence from expensive
and time consuming procedures, such as FACS and MCS
(see Table 1), and the flexible adjustment of cell yields
makes RS+DGC an attractive purification method for a
wide spectrum of downstream applications, particularly
expression analysis utilising microarrays, in which a CLL
purity of >90% is desirable.
Methods
Peripheral blood (PB) samples of CLL patients were
obtained as part of a study approved by the Peter MacCa-
llum Ethics of Human Research Committee. The white
blood cell (WBC) count ranged from 7.81 to 437.08 ×
106/ml and averaged 76.1 × 106/ml. The diagnosis of CLL
was based on earlier examination of the patients' blood
film and immunophenotyping for CD3, CD4, CD5, CD8,
CD10, CD16, CD19, CD20, CD22, CD23, CD38, CD45,
CD56, FMC7 and surface immunoglobulin light chain
expression.
Blood from CLL patients was incubated with RosetteSep™
(StemCell Technologies Inc., Vancouver, British Colum-
bia, Canada) (RS) at a concentration of 70 μl/ml PB in the
dark at room temperature for 20 minutes with gentle
manual swirling every 5 minutes. As a control, an aliquot
of the same sample was processed the same way except
without addition of RS. After incubation, both aliquots of
blood were diluted with 4 volumes (rather than 2 vol-
umes as recommended by the manufacturer) of Dul-
becco's phosphate buffered saline (PBS) containing 2%
foetal bovine serum as otherwise we found that blood
samples with high WBC counts were insufficiently diluted
for efficient separation. The samples were then underlaid
with 3 ml Lymphocyte Separation Medium (MP Biomed-
icals, Aurora, OH) and centrifuged for 20 minutes at
1,200 g. The enriched cells were subsequently harvested
from the interface and washed once in 2 volumes Dul-
becco's PBS with 2% foetal bovine serum by centrifuging
for 10 minutes at 200 g.
The purity of the enriched cell population was analysed by
staining with a panel of fluorescently labelled antibodies
(BD Biosciences, San Jose, CA) in three different tubes.
(Tube 1: CD5-FITC, CD10-PE, CD19-PerCP and CD45-
APC. Tube 2: FMC7-FITC, CD23-PE, CD19-PerCP and
Table 1: Comparison of the discussed four different enrichment approaches
DGC RS+DGC DGC+MCS DGC+FACS
Purity ca. 70% a ca. 93% a > 98% d 90 – 95% f
CD5+/CD19+ CD5+/CD19+ > 93% e CD5+/CD19+
CD19+
86% (± 14%) b
CD19+
90% (± 7%) c
CD5+/CD19+/CD23+
Time of procedure < 60 mins. < 90 mins. > 120 mins (increasing with 
sample volume)
> 120 mins (increasing with 
sample volume)
Selection method negative negative positive positive
Limitations highly depending on WBC 
count
dependent on WBC count 
when < 20 × 106 cells/ml 
PB
long process time and 
expensive
long process time and very 
expensive
cost low medium medium-high high
Required Infra-
structure
centrifuge centrifuge centrifuge + MCS Sorter centrifuge + FACS sorter
DGC: density gradient centrifugation, RS+DGC: RosetteSep incubation prior to DGC, DGC+MCS: DGC and subsequent magnetic cell sorting, 
DGC+FACS: DGC and subsequent fluorescent activated cell sorting.
a average purity experienced in our study
b purity reported by Haslinger et al., 2004
c purity reported by Falt et al., 2005
d purity reported by Rosenwald et al., 2004 and Wiestner et al., 2003
e Huttman et al., 2006
f purity reported by Stankovic et al., 2004BMC Biotechnology 2008, 8:6 http://www.biomedcentral.com/1472-6750/8/6
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CD45-APC. Tube 3: CD22-FITC, CD38-PE, CD20-PerCP
and CD45-APC). Data acquisition was carried out using a
FACScalibur-cytometer (BD Biosciences) and Cell Quest
software (BD Biosciences). Ungated data analysis was
conducted using Cytomics RXP software (Beckman Coul-
ter, Fullerton, CA).
The diagnosis of CLL was reconfirmed by assessing posi-
tivity for CD5, CD19, CD23 and CD45, weak positivity
for CD20; weak positivity or negativity for CD22 and
FMC7 and negativity for CD10. After confirming the CLL
diagnosis, the CLL purity was assessed by the co-expres-
sion of CD5 and CD19.
RNA was extracted from RS+DGC enriched CLL cells by
applying a combination of the Trizol-protocol (Invitro-
gen, Carlsbad, CA, USA) and the RNeasy Micro Kit (Qia-
gen, Hilden, Germany). The RNA Integrity Number (RIN)
of the extracted RNA was determined using the 2100 Bio-
analyzer (Agilent, Santa Clara, CA) according to the man-
ufacturer's protocol.
Abbreviations
CLL Chronic Lymphocytic Leukaemia
DGC density gradient centrifugation
FACS fluorescent-activated cell sorting
MCS magnetic cell sorting
PB peripheral blood
PBS Dulbecco's phosphate buffered saline
PCR polymerase chain reaction
RIN RNA Integrity Number
RS RosetteSep™
RS+DGC addition of RosetteSep B-cell enrichment cock-
tail prior to density gradient centrifugation
RT-PCR reverse transcription polymerase chain reaction
WBC white blood cell
Authors' contributions
SE adapted the methodology, carried out the laboratory
work, participated in experimental design, and drafted the
manuscript. DC participated in the experimental design
and supplied clinical specimens. DW participated in the
experimental design and supplied clinical specimens. PG
assisted with the immunophenotyping. JFS supplied clin-
ical specimens. AD participated in experimental design,
supervised the laboratory work and brought the manu-
script to its final form. All authors read and approved the
final manuscript.
Additional material
Acknowledgements
We thank Nancy Messino for assisting with the immunophenotyping and 
Sophia Halley, Ida Candiloro, Angela Tan, Lasse Kristensen, Michael Krypuy 
and Chelsee Hewitt for critical reading of the manuscript. Funding for this 
study was from grants from the CLL Global Research Foundation to AD 
Additional file 1
CD5/CD19 immunophenotyping of sample CLL22 (1), CLL35 (2) and 
CLL36 (3) after RS+DGC enrichment using either 50 μl (A), 60 μl (B), 
70 μl (C) or 80 μl (D) RosetteSep/ml whole blood. Data indicates that a 
concentration of 70 μl RosetteSep/ml whole blood gives the highest puri-
ties of CD5+ CD19+ cells.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1472-
6750-8-6-S1.ppt]
Additional file 2
CD5/CD19 immunophenotyping of sample CLL2 after DGC (left) and 
after RS+DGC enrichment (right). Figure shows the CD5/CD19 cell sur-
face expression of one sample (CLL2) post DGC, and post RS+DGC 
enrichment determined by immunophenotyping. The RS+DGC enrich-
ment lead to a significant increase in the proportion of the CD5+ CD19+ 
cells.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1472-
6750-8-6-S2.ppt]
Additional file 3
White Blood Cell (WBC) counts of fresh CLL peripheral blood samples 
and their examination for CLL purity after density gradient centrifugation 
DGC and RosetteSep incubation prior to DGC (RS+DGC) enrichment. 
The data is sorted by ascending WBC count. RNA Integrity Numbers 
(RIN) for RNA extracted from CLL cells after RS+DGC enrichment are 
shown. The figure shows the WBC counts of all CLL peripheral blood sam-
ples and the respective purity of the CD5- CD19+, CD5+ CD19+, CD5- 
CD19- and CD5+ CD19- fractions after DGC and after RS+DGC. This 
table also displays RNA Integrity Numbers for RNA extracted from puri-
fied CLL cells using RS+DGC.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1472-
6750-8-6-S3.pdf]
Additional file 4
White blood cell (WBC) counts of fresh CLL peripheral blood (PB) sam-
ples and yields and purities after RosetteSep incubation prior to density 
gradient centrifugation (RS+DGC) enrichment. The data is sorted by 
ascending WBC count. The figure shows the WBC counts of all CLL 
peripheral blood samples and the respective cell yield and purity of the 
CD5+ CD19+ fractions after DGC and after RS+DGC.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1472-
6750-8-6-S4.pdf]Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Biotechnology 2008, 8:6 http://www.biomedcentral.com/1472-6750/8/6
Page 5 of 5
(page number not for citation purposes)
and JFS and Reece Australia to DW and AD. SE also acknowledges his aca-
demic supervisors at the Heinrich Heine University, Prof. Dr. Heinz Mehl-
horn and Prof. Dr. Christopher Poremba.
References
1. Staal FJ, Cario G, Cazzaniga G, Haferlach T, Heuser M, Hofmann WK,
Mills K, Schrappe M, Stanulla M, Wingen LU, van Dongen JJ, Schlegel-
berger B: Consensus guidelines for microarray gene expres-
sion analyses in leukemia from three European leukemia
networks.  Leukemia 2006, 20:1385-92.
2. de Ridder D, van der Linden CE, Schonewille T, Dik WA, Reinders
MJ, van Dongen JJ, Staal FJ: Purity for clarity: the need for purifi-
cation of tumor cells in DNA microarray studies.  Leukemia
2005, 19:618-27.
3. Haslinger C, Schweifer N, Stilgenbauer S, Dohner H, Lichter P, Kraut
N, Stratowa C, Abseher R: Microarray gene expression profiling
of B-cell chronic lymphocytic leukemia subgroups defined by
genomic aberrations and VH mutation status.  J Clin Oncol
2004, 22:3937-49.
4. Falt S, Merup M, Tobin G, Thunberg U, Gahrton G, Rosenquist R,
Wennborg A: Distinctive gene expression pattern in VH3-21
utilizing B-cell chronic lymphocytic leukemia.  Blood 2005,
106:681-9.
5. Stankovic T, Hubank M, Cronin D, Stewart GS, Fletcher D, Bignell
CR, Alvi AJ, Austen B, Weston VJ, Fegan C, Byrd PJ, Moss PA, Taylor
AM: Microarray analysis reveals that TP53- and ATM-mutant
B-CLLs share a defect in activating proapoptotic responses
after DNA damage but are distinguished by major differ-
ences in activating prosurvival responses.  Blood 2004,
103:291-300.
6. Rosenwald A, Chuang EY, Davis RE, Wiestner A, Alizadeh AA, Arthur
DC, Mitchell JB, Marti GE, Fowler DH, Wilson WH, Staudt LM:
Fludarabine treatment of patients with chronic lymphocytic
leukemia induces a p53-dependent gene expression
response.  Blood 2004, 104:1428-34.
7. Wiestner A, Rosenwald A, Barry TS, Wright G, Davis RE, Henrickson
SE, Zhao H, Ibbotson RE, Orchard JA, Davis Z, Stetler-Stevenson M,
Raffeld M, Arthur DC, Marti GE, Wilson WH, Hamblin TJ, Oscier
DG, Staudt LM: ZAP-70 expression identifies a chronic lym-
phocytic leukemia subtype with unmutated immunoglobulin
genes, inferior clinical outcome, and distinct gene expression
profile.  Blood 2003, 101:4944-51.
8. Huttmann A, Klein-Hitpass L, Thomale J, Deenen R, Carpinteiro A,
Nuckel H, Ebeling P, Fuhrer A, Edelmann J, Sellmann L, Duhrsen U,
Durig J: Gene expression signatures separate B-cell chronic
lymphocytic leukaemia prognostic subgroups defined by
ZAP-70 and CD38 expression status.  Leukemia 2006,
20:1774-82.
9. Peters CE, Woodside SM, Eaves AC: Isolation of subsets of
immune cells.  Methods Mol Biol 2005, 302:95-116.